In support of this hypothesis, inhibition of the IL-33/ST2 pathway via neutralizing ST2 antibodies or using ST2 KO mice in models of autoimmune disease (e.g., dextran-induced colitis, collagen-induced or autoantibody-induced arthritis) demonstrated reduced severity of disease pathology (75–77). Here, IL33 is linked to autoimmune disease.